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Abstract
Biomarker-guided initiation of antibiotic therapy has been studied in four conditions: acute pancreatitis, lower
respiratory tract infection (LRTI), meningitis, and sepsis in the ICU. In pancreatitis with suspected infected necrosis,
initiating antibiotics best relies on fine-needle aspiration and demonstration of infected material. We suggest that
PCT be measured to help predict infection; however, available data are insufficient to decide on initiating antibiotics
based on PCT levels. In adult patients suspected of community-acquired LRTI, we suggest withholding antibiotic
therapy when the serum PCT level is low (<0.25 ng/mL); in patients having nosocomial LRTI, data are insufficient to
recommend initiating therapy based on a single PCT level or even repeated measurements. For children with
suspected bacterial meningitis, we recommend using a decision rule as an aid to therapeutic decisions, such as the
Bacterial Meningitis Score or the Meningitest®; a single PCT level ≥0.5 ng/mL also may be used, but false-negatives
may occur. In adults with suspected bacterial meningitis, we suggest integrating serum PCT measurements in a
clinical decision rule to help distinguish between viral and bacterial meningitis, using a 0.5 ng/mL threshold. For
ICU patients suspected of community-acquired infection, we do not recommend using a threshold serum PCT
value to help the decision to initiate antibiotic therapy; data are insufficient to recommend using PCT serum
kinetics for the decision to initiate antibiotic therapy in patients suspected of ICU-acquired infection. In children,
CRP can probably be used to help discontinue therapy, although the evidence is limited. In adults, antibiotic
discontinuation can be based on an algorithm using repeated PCT measurements. In non-immunocompromised
out- or in- patients treated for RTI, antibiotics can be discontinued if the PCT level at day 3 is < 0.25 ng/mL or has
decreased by >80-90%, whether or not microbiological documentation has been obtained. For ICU patients who
have nonbacteremic sepsis from a known site of infection, antibiotics can be stopped if the PCT level at day 3
is < 0.5 ng/mL or has decreased by >80% relative to the highest level recorded, irrespective of the severity of the
infectious episode; in bacteremic patients, a minimal duration of therapy of 5 days is recommended.
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Biomarkers and initiation of antibiotic therapy
According to the preset selection criteria (see part I), the
panel reviewed four conditions in which the potential
clinical role of biomarkers has been studied: acute pan-
creatitis, respiratory tract infections, meningitis, and sep-
sis in the ICU.
Acute pancreatitis in adults
The clinical presentation and severity of patients having
acute pancreatitis varies considerably, from a mild ab-
dominal discomfort to multiple organ failure and death.
The potential role of biomarkers in this condition should
thus be twofold: 1) a prognostic value, to help define the
most appropriate therapeutic approach, by predicting
the severity of the disease and accurately select those pa-
tients needing close monitoring in the ICU; and 2) a
diagnostic value, to help identify those patients having
infected pancreatic necrosis, who might need drainage
or surgery. Mofidi et al. [1] have recently reviewed the
potential role of PCT in answering these two questions,
by analysing 12 observational studies [2-9] totalling
956 patients. The threshold PCT value used in these
studies to predict the severity of pancreatitis varied from
0.25 to 1.8 mg/L, with an associated combined sensitiv-
ity of 0.72 (0.65-0.78), a specificity of 0.86 (0.83-0.89),
and an area under the receiver operating curve
(AUROC) of 0.87. In the seven studies (n = 264 patients)
examining the value of PCT for predicting the presence
of infected necrosis [2-5,7-9], the threshold value varied
across studies between 0.48 and 3.5 mg/L, with an asso-
ciated sensitivity of 0.8 (0.71-0.88), a specificity of 0.91
(0.87-0.94), and an AUROC of 0.91 (Table 1). In these
seven studies, PCT levels were confronted to microbio-
logical results obtained from fine-needle biopsy and cul-
ture of intra-abdominal collections, taken as the “gold
standard.”
Other less commonly measured biomarkers (IL-6, IL-8
, sTREM-1, TNF-α) also have been compared to PCT for
their ability to help answer the two questions above.
These biomarkers provided AUROC comparable to
those of PCT, both in terms of prognostic value and of
diagnosis of infected necrosis [2,4-6,9,10]. Conversely,
CRP levels appear less discriminatory for the prediction
of infected necrosis [2]. No study has evaluated the value
of repeated PCT measurements to predict infection, and
no study has evaluated the impact on patients’ outcome
of the initiation of antibiotic therapy guided by a bio-
marker level in patients suspected of infected necrosis.
In summary, we suggest that PCT be measured to help
predict infection in patients suspected of infected necro-
sis during acute pancreatitis; it is however difficult from
the available literature to define a precise threshold value
(0.5-1.0 mg/L). A PCT value above the threshold might
reinforce the clinician’s judgment that a fine-needle
aspiration and culture is needed to confirm infection,
while a value below this threshold might help deferring
this intervention and proceed with watchful waiting.
There is insufficient data to recommend initiating anti-
biotic therapy based on biomarker levels: this decision is
based on a careful repeated evaluation of the patient and
on the results of fine-needle aspiration material, which
currently remains the cornerstone for the decision to
initiate or maintain antibiotic therapy.
Lower respiratory tract infection in adults
Antibiotics often are prescribed in excess to patients
having a clinical syndrome of community-acquired lower
respiratory tract infection (LRTI). Despite the usually
viral aetiology of their illness, an estimated 75% of pa-
tients with acute bronchitis receive antibiotics [11]; in-
deed, clinical presentation does not allow the distinction
between bacterial and viral infection, which encourages
physicians to err on the “safe side” and prescribe antibi-
otics. Communication campaigns inciting primary phy-
sicians to limit unnecessary prescriptions for LRTI have
a moderate impact, which is difficult to maintain over
time [12,13]. In this context, the addition of biomarker
measurements to the clinical evaluation of such patients
may have two main potential effects: improve the diag-
nostic accuracy, and reassure the patient and the phys-
ician that antibiotic therapy is unnecessary.
An abundant literature is available on PCT-guided ini-
tiation of antibiotic therapy in patients suspected clinic-
ally of having LRTI, providing a high-level of evidence.
To date, 11 randomised, controlled studies using a simi-
lar approach have been published and provide consistent
results [14-25]. All these studies have used a similar
algorithm [26-29] to help decide on the initiation and
continuation of antibiotic therapy, with a lower PCT
threshold of <0.25 ng/mL to encourage physicians to
withhold antibiotic prescription. The absolute risk re-
duction of antibiotic administration varies between 11%
and 72% across these studies compared with “usual care”
based on local recommendations and physicians’ judg-
ment and preferences (Table 2). In one study, however,
antibiotic prescriptions increased by 6% with PCT-
guided therapy [19]. It also should be noted that the
0.25 ng/mL threshold may be less reliable in the elderly,
where an 8% false-positive rate has been reported [30].
Among the 14 studies of PCT-guided therapy for LRTI
reviewed by the Cochrane Collaboration [31,32], only 3
enrolled patients with a nosocomial infection (hospital-
acquired or ventilator-associated) [33-35], 2 of which
evaluated the impact of PCT-guided therapy on the initi-
ation of treatment [33,34]. However, nosocomial acquisi-
tion of infection is identifiable only in the study by
Bouadma et al. [33], and only 5% (n = 141) of all patients
enrolled fulfilled this criteria; nearly all patients in this
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Table 1 Use of biomarkers for the diagnosis of infected necrosis secondary to acute pancreatitis
Marker Study Study design Nb of
patients,
n
Level of
evidence
Biomarker tested and groups compared Main results
1st author,
[Ref]
PCT/CRP Rau B, [2] Observational 61 Low Comparison of PCT and CRP levels
between 3 groups:
AUROC for the diagnosis of infected necrosis:
Oedematous pancreatitis (n = 22) PCT (>1.8 mg/L) = 0.95 (Se: 95%, Sp: 88%),
Sterile necrosis (n = 18) CRP (>300 mg/L) = 0.86 (Se:86%, Sp: 75%);
p < 0.02
Infected necrosis (n = 21) according to
imaging/surgery/microbiological data
PCT/CRP/GCSF Muller CA, [3] Observational 64 Low Comparison of PCT, G-CSF, and CRP
between patients having oedematous
pancreatitis (n = 29)
AUROC for diagnosing infected necrosis:
CRP (>250) = 0.79 (Se: 83, Sp: 70%), PCT
(0.45) = 0.77 (Se: 92%, Sp: 65%), AUC G-CSF
(101) = 0.72 (Se: 92%, Sp: 48%)Noninfected necrosis (n = 23)
Infected necrosis (n = 12) according to
imaging/surgery/microbiological data
PCT/CRP/IL8 Rau B, [4] Observational 50 Low Comparison of PCT, IL8, and CRP levels
between patients with:
AUROC for diagnosing infected necrosis:
Oedematous pancreatitis (n = 18) CRP (>300) = 0.84 (Se: 83, Sp: 78%),
Non-infected necrosis (n = 14) PCT (>1.8) = 0.97 (Se: 94%, Sp: 90%)
Infected necrosis (n = 18) according to
imaging/surgery/microbiological data
IL-8 (112) = 0.78 (Se: 72%, Sp: 75%)
PCT/CRP/IL6/TNF Riche F, [5] Observational 48 Low Comparison of PCT, IL-6, TNF-α, and CRP
between patients having
AUROC for diagnosing infected necrosis:
- Noninfected necrosis (n = 33) CRP = 0.76,
- Infected necrosis (n = 15), according to
imaging/surgery/microbiological data
PCT = 0.78,
IL 6 = 0.77,
TNF α = 0.5
PCT Purkayastha S, [6] Literature review
(5 studies)
206 Low Assessing the value of PCT for diagnosing
infected pancreatic necrosis
Threshold values for PCT vary from 0.48 to 2;
Sensitivity: 0.73 to 0.94
Specificity: 0.65 to 1
PCT/IL6/TNF/sTREM1 Lu Z, [7] Observational 30 Low Comparison of PCT, IL-6, TNF-α, and
sTREM-1 levels in serum and drainage
fluid between patients having:
Biomarker levels in drainage fluid: No difference
between the two groups for CRP, TNF-α,
and IL-6 levels
- Noninfected necrosis (n = 12), or - sTREM1 (287), AUC = 0.97 (Se = 94, Sp = 92)
- Infected necrosis (n = 18), according to
imaging/surgery/microbiological data
- PCT (2.1): AUC = 0.9 (Se = 86, Sp = 91).
Lower AUCs for serum levels:
PCT: 0.79; sTREM1: 0.73
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Table 1 Use of biomarkers for the diagnosis of infected necrosis secondary to acute pancreatitis (Continued)
PCT Olah A, [8] Observational 24 Low Comparison of PCT levels in patients having Serum PCT level >0.5 predicts infected necrosis
with Se = 75% and Sp = 83%.
- Noninfected necrosis (n = 12) Fine-needle aspiration predicts infection
with Se = 92% and Sp = 100%.
- Infected necrosis (n = 12)
According to results of fine-needle
aspiration and culture and surgery
PCT/IL6/sICAM1 Mandi Y, [9] Observational 30 Low Comparison of PCT, IL-6, and sICAM-1
between patients with
Only PCT (threshold >1 mg/L) allowed to
distinguish patients with or without infected
necrosis (Se = 90%; Sp = 100%).
Noninfected necrosis (n = 10)
Infected necrosis (n = 10), according
to results of biopsy and culture.
PCT Mofidi R, [1] Literature review
(7 studies)
264 Low Assessment of PCT serum levels for the
diagnosis of infected pancreatic necrosis
Threshold values vary from 0.48 to 3.5 mg/L,
with a sensitivity of 0.63 to 0.92 and specificity
of 0.71 to 0.97.
Summary table: infected necrosis in acute pancreatitis
Number of studies, n Total number of patients, n Highest level of evidence Directness* Consistency of results** Overall strength of evidence
7 264a Low Yes Yes Moderate
aNumber of patients included in diagnostic studies of infected pancreatic necrosis.
*Directness: studies provide evidence of a direct association between a treatment or a given risk factor and a judgment criterion.
**Consistency: results from studies of similar level of evidence are not contradictory.
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Table 2 Role of biomarkers in the initiation of antibiotic therapy for lower respiratory tract infection
Biomarker Study (ref) Study design Nb
patients, n
(setting)
Level of
evidence
End-point Main results, absolute risk reduction
(ARR) or odds ratio (OR; 95% CI)
1st author, [Ref]
PCT Stolz D, [20] Single-centre, randomised,
controlled open study
208 High Antibiotic exposure and rate of
initiation of antibiotic therapy,
based on PCT level > 0.25 μg/L
ARR = 32% (40% vs. 72%) of antibiotic
prescriptions in the PCT-guided group.
(AECB)
Ab exposure OR = 0.56 [0.43-0.73]
PCT Schuetz P, [25] Multicentre, open RCT 1359 High Antibiotic exposure ARR = 12% (75.4% vs. 87.7%) in PCT group,
Overall antibiotic exposure = - 35%
(5.7 vs. 8.7 days).
Noninferiority study (ED) Based on a PCT level > 0.25 μg/L
for initiating prescription.
PCT Christ-Crain M, [18] Single-centre open RCT 302 High Antibiotic initiation rate ARR = 14% (85% vs. 99%) in initial
antibiotic prescription in PCT group
(ED, ward) Antibiotic exposure
Based on a PCT level > 0.25 μg/L
to initiate therapy
Overall ab exposure: OR = 0.52 [0.48–0.55]
PCT Kristoffersen KB, [19] Single-centre, open, RCT 210 High Antibiotic prescription rate, based
on a PCT level > 0.25 μg/L to
initiate therapy in PCT group
3% increase in antibiotic prescription (88%
vs. 85%) in the PCT group
(ED, ward)
PCT Long W, [23] Single-centre, open RCT 127 High Antibiotic prescription rate, based
on a PCT level > 0.25 μg/L in the
PCT group
ARR = 11% of antibiotic prescriptions in
the PCT group
(ED)
PCT Long W, [22] Single-centre, open RCT 156 High Antibiotic prescription rate, based
on a PCT level > 0.25 μg/L in the
PCT group
ARR = 13% of antibiotic prescriptions in
the PCT group
(ED)
PCT Burkhardt O, [16] Single-centre, open RCT,
noninferiority
550 High Antibiotic prescription rate, based
on a PCT level > 0.25 μg/L in the
PCT group
ARR = 15% (21.5% vs. 36.7%) for antibiotic
prescription rate in the PCT group
(PC)
PCT Briel M, [15] Multicentre, open RCT, noninferiority 458 High Antibiotic prescription rate, based
on a PCT level > 0.25 μg/L in the
PCT group
ARR = 72% [95% CI 66-78] for antibiotic
prescription rate in the PCT group
(PC)
PCT Schuetz P, [30] Meta-analysis of 14 RCTs 3 119 High Risk reduction of initial antibiotic therapy:
OR = 0.24 (95% CI, 0.2-0.29)
Overall antibiotic exposure:
OR = 0.1 (95% CI = 0.07-0.14), without
difference in mortality rates
PCT Van der Meer V, [28] Literature review on the use of
CRP (13 studies)
13 High Prediction of LRTI Bacterial LRTI predicted with a sensitivity
varying from 8% to 99% and a specificity
varying from 27% to 95%
PCT Schuetz P, [29] Review of 8 RCTs using an PCT-based
algorithm for the initiation of
antibiotic therapy
3 457 High Antibiotic prescription rate ARR varying from 6% to 72%
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Table 2 Role of biomarkers in the initiation of antibiotic therapy for lower respiratory tract infection (Continued)
CRP Cals JW, [24] Multicentre, open cluster-RCT,
testing a CRP-based algorithm
431 High Antibiotic prescription rate and
antibiotic exposure, based on a
CRP value < 20 : no antibiotic;
CRP >100 : atb recommended,
and 20<CRP<99 : reassess for
possible therapy
ARR = 22% (31% vs. 53%) of initial
antibiotic prescriptions in the CRP group
Overall antibiotic exposure: - 13%
(45% vs. 58%)
PCT Christ-Crain M, [17] Multicentre, open, cluster-RCT 243 High Antibiotic prescription rate, based
on a PCT level > 0.25 μg/L in the
PCT group
ARR = 39% for antibiotic prescription
rate in the PCT group
(ED)
Summary of evidence table: Lower respiratory tract infection
Number of
studies, n
Total number of
patients, n
Highest level of evidence Directness* Consistency** Overall strength of evidence
12 4 412 High Yes Yes Strong
*Directness: studies provide evidence of a direct association between a treatment or a given risk factor and a judgment criterion.
**Consistency: results from studies of similar level of evidence are not contradictory.
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subgroup were administered antibiotics (99% in the
PCT-guided therapy group and 100% in controls). Re-
peated measurements might be helpful for initiating
antibiotics in this subgroup; however, the few data avail-
able on a limited number of patients (n = 89 patients)
[36] do not allow making a recommendation in this
regard.
In summary, we suggest withholding antibiotic therapy
in adult patients suspected of community-acquired LRTI
and having a serum PCT level <0.25 ng/mL; if clinical
suspicion is high, it is however recommended to repeat
the PCT measurement at a 6-h interval and reassess
the therapeutic approach, accounting for new clinical
findings. In patients having nosocomial LRTI, data are
insufficient to recommend tailoring the therapeutic ap-
proach based on a single PCT level or even repeated
measurements.
Meningitis
Childhood meningitis
Most acute meningitis in children is of viral aetiology
and evolves favourably [37,38]. Despite their relatively
low prevalence, acute bacterial meningitis are severe in-
fections, often resulting in debilitating sequels or even
death [39]; thus, antibiotic therapy is recommended in
children presenting with acute meningitis, at least until
cerebrospinal fluid (CSF) cultures are available, i.e.,
within the first 48–72 h [40]. The risk-benefit ratio and
costs associated with this prudent approach is likely un-
favourable, because it involves numerous unnecessary
hospitalisations, increased costs, and side effects of treat-
ments, including selection of resistant organisms [41].
Biomarkers might help to reduce these unwanted effects
[42,43]. Ideally, a good biomarker would have 100% sen-
sitivity for the diagnosis of bacterial meningitis, together
with an acceptable specificity [38]; however, when used
alone, available biomarkers (PCT, CRP, IFN-Υ, etc.) have
sensitivities and specificities that do not appear high
enough to base a therapeutic decision on their results given
the risks incurred in case of a false-negative test [44,45].
To overcome this problem, several groups have pro-
posed decision rules combining clinical criteria and bio-
marker results [46-50]. The Bacterial Meningitis Score
(BMS) [46] has been reported to have 100% sensitivity
and 67% specificity for the detection of bacterial menin-
gitis and is easily applicable at the bedside. This decision
rule encourages ambulatory treatment of children having
meningitis (i.e., a CSF leucocytes count ≥7/mm3) if none
of the following five criteria is present: seizures, blood
polymorphonuclear (PMN) cells count ≥10,000/mm3, dir-
ect examination of CSF positive, CSF protein level ≥0.8 g/L,
or CSF PMN ≥1000/mm3. The BMS has undergone ex-
ternal validation on the large database of the French
national registry for childhood bacterial meningitis
(ACTIV-GPIP) [51]. Of 889 children with confirmed
bacterial meningitis, 884 were correctly identified by the
BMS rule (sensitivity = 99.6%; 95% confidence interval
(CI) 98.9-99.8) with a specificity >60%. Thus, despite
these near-perfect results, a few patients with bacterial
meningitis (n = 5) were not detected by the BMS
[52]; that the BMS can have a few false-negatives also
was confirmed by a recent meta-analysis [53]. The
Meningitest® (European patent EP1977244) has been
subsequently proposed to refine the BMS and avoid
these false-negatives, by omitting some variables of poor
discriminatory power and introducing the serum PCT
level [45,54]. The Meningitest® rule suggests initiating
antibiotic therapy if at least one of the following criteria
is present: seizures, toxic appearance, purpura, PCT
level ≥0.5 ng/mL, positive CSF Gram stain, or CSF
protein level ≥0.5 g/L. External validation of the
Meningitest® has been performed on an European database
of 198 patients (including 96 with bacterial meningitis),
where its sensitivity and specificity were respectively of
100% (95% CI 96–100) and 36% (95% CI 27–46) for the
diagnosis of bacterial meningitis, whereas correspond-
ing values for the BMS were 100% (95% CI 96–100)
and 52% (95% CI 42–62) [55]. A single serum PCT
level ≥0.5 ng/mL has similar sensitivity and specificity
as the BMS, whereas combining CRP with CSF protein
levels provided lower performances.
In summary, for children with suspected bacterial
meningitis, we recommend using a decision rule as an
aid to triage decisions and antibiotic prescribing, such as
the BMS (more specific, but with a few false-negatives)
or the Meningitest® (less specific, but no false-negative
described to date). A single PCT level ≥0.5 ng/mL also
may be used, but false-negatives may occur.
Adult meningitis
The potential role of biomarkers in the management of
meningitis has been much less studied in adults than in
children. Similarly to children, the use of a clinical decision
rule to distinguish between viral and bacterial meningitis is
recommended in adults [56]. For example, the French
2008 consensus conference on meningitis recommended
using one of three decision rules: the rule developed by
Hoen et al. [57], the BMS, or the Meningitest® [56]. It
should be noted that the former rule has insufficient sensi-
tivity in children (94%), with a risk of false-negatives [45].
Knudsen et al. have examined the impact of various bio-
markers in the diagnostic workup of 55 adult patients with
meningitis [58]. These authors found an AUROC of 0.91,
0.87, and 0.72 for CRP, PCT, and sCD 163, respectively,
and concluded that CRP and PCT levels could be useful
when combined with results of CSF examination to help
diagnose bacterial meningitis. One recent study [59]
included 151 patients admitted to an adult emergency
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department with suspected of bacterial meningitis and a
negative direct examination of CSF, to assess the diagnos-
tic value of CRP, PCT, and CSF leucocytes count. The
AUROC of PCT and CRP were 0.98 (95% CI, 0.83-1.0)
and 0.81 (95% CI, 0.58-0.92), respectively; however, the
small number of patients with confirmed bacterial menin-
gitis (n = 18) limits the inferences from this study. Of
note, the CSF leucocytes count appeared to have little dis-
criminatory value (AUC = 0.59) in that study. In another
study of 30 patients (including 16 having bacterial menin-
gitis), Schwarz et al. [60] found that PCT had a sensitivity
of 69% and a specificity of 100% for diagnosing bacterial
meningitis. In another larger prospective study that in-
cluded 112 adult patients admitted to the hospital for
meningitis (90 viral and 22 bacterial), Viallon et al. [61]
found that a serum PCT value >0.93 ng/ml was 100% sen-
sitive for the diagnosis of bacterial meningitis; conversely,
a CSF lactate level <3.2 mmoles/L had a 100% NPV
(Table 3). Low CRP levels have high NPV, but have not
been shown to contribute markedly to the diagnostic ap-
proach [62]. The 2008 French consensus conference on
management of acute bacterial meningitis [56] concluded
that these biomarkers could be helpful for diagnosing bac-
terial meningitis in adults, pointing out that a threshold
value for serum PCT of 0.5 ng/mL had a high sensitivity
(99%; 95% CI, 97–100) and specificity (83%; 95% CI, 76–
90), and that bacterial meningitis could be considered very
unlikely when PCT was <0.5 ng/mL or CSF lactate was
below 3 mmoles/L.
In summary, we suggest integrating serum PCT mea-
surements in a clinical decision rule for meningitis in
adults to help distinguish between viral and bacterial
meningitis, using a threshold of 0.5 ng/mL.
Adult intensive care patients
Most controlled studies performed in intensive care pa-
tients have examined the value of biomarkers to limit
the duration of antibiotic therapy, and few have concen-
trated on its initiation. Although a recent meta-analysis
suggests that PCT is helpful for differentiating sepsis
from SIRS [63], the initiation of antibiotic therapy in
ICU patients has been assessed in only two randomised
open studies testing a PCT-based algorithm (Table 4)
[33,34]. In the study by Layios et al. [34], there was no
difference in the rate of initiation of therapy between the
control group and the PCT-based group (where antibi-
otics were strongly discouraged if PCT was lower than
0.25 ng/mL, and strongly encouraged if PCT was higher
than 1 ng/mL). In the multicentre study performed by
Bouadma et al. [33] and using a similar algorithm, the
risk reduction of initiating antibiotic therapy varied be-
tween 5% and 13% across centres. However, the small
number of patients having CAP (n = 69) and the very
low observance of the algorithm for withholding
antibiotics when PCT levels were low (6%) in this study
do not allow concluding on this point.
Relying on changes in PCT levels might be helpful for
the initiation of antibiotic therapy in intensive care pa-
tients suspected of ICU-acquired infection; however,
currently available data (on a total of 207 patients) are
insufficient to base a recommendation on these [36,64].
One randomized, controlled study that enrolled 604 ICU
patients has tested the diagnostic value of daily measure-
ments of serum PCT levels (using a threshold of 1 ng/mL
to rapidly initiate a diagnostic workup and protocolised
therapy) [65]. The length of ICU stay and of mechanical
ventilation were actually higher in the PCT arm (without
difference in 28-day mortality), and time to adequate ther-
apy was not lower (except for patients with bacteremia).
Of note, antibiotic consumption was significantly higher
in the PCT arm, as well as the total number of days spent
in the ICU with three or more antibiotics.
In summary, we do not recommend using a threshold
serum PCT value to help in the decision to initiate anti-
biotic therapy in ICU patients suspected of community-
acquired pneumonia. There are insufficient data available
to recommend using repeated PCT measurements and
serum kinetics for the decision to initiate antibiotic ther-
apy in ICU patients suspected of ICU-acquired infection.
When can biomarkers help the decision to stop antibiotic
therapy?
Given the number of studies examining this question and
the high level of evidence generated, investigating this
question was limited to examining randomized, controlled
studies having tested a strategy based on biomarker meas-
urement(s), to the exclusion of all other study designs. All
studies in hospitalised patients used serum PCT level
measurements, as there is no study testing the impact of
using another biomarker in this specific indication;
whereas several studies have tested the value of CRP for
initiating antibiotics in pre-hospital care [24,66-68], none
examined its potential impact on discontinuation of anti-
biotics, although several studies are ongoing (see http://
www.clinicaltrials.gov/ct2/results?term=c+reactive+protein+
and+duration&recr=&rslt=&type=&cond=&intr=&outc=&
spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&st-
ate3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&-
lup_e=). Accordingly, only studies using PCT levels are
considered below.
How can biomarkers be used to help decide on
discontinuing antibiotic treatment?
To date, 14 trials have examined the clinical impact of
PCT-guided antibiotic therapy and its discontinuation
[15-20,22,23,33,35,69,70,72,73]. Nine of these focused on
the latter objective; four were conducted in prehospital
care or emergency room, whereas the remaining five
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Table 3 Studies of biomarkers in the diagnosis of bacterial meningitis (BM) and its distinction from viral meningitis (VM)
Marker Study 1st
author, [ref]
Study design Number of
patients, n
Level of
evidence
End-point Main result
Absolute risk reduction (RR)
PCT Gendrel D, [42] Single-centre
observational study
59 children
(18 BM, 41 VM)
Very low Comparison of PCT and CRP level in
patients with bacterial or viral meningitis
A serum PCT level >0.5 μg/L is associated with
bacterial meningitis (Se = 94%; Sp = 100%).
Large overlap for CRP values
PCT/CRP/
INF-ϒ
Marc E, [43] Single-centre
observational study
58 viral Very low Antibiotic initiation and hospital days, based on
a serum PCT < 0.5 to not initiate or stop antibiotics.
If PCT >0.5, antibiotics stopped if negative cultures
and/or INF or PCR (+) in CSF
41 patients did not receive antibiotics; antibiotics
stopped in 15/17 pts treated by day 1 or 2,
because of a PCT < 0.5.
(enterovirus
outbreak)
Children
(2 mo – 14 yr)
Hospital days reduced to 2 days.
PCT/CRP/
sCD 163
Knudsen T, [58] Single-centre
observational study
(ID department)
55 adult patients
suspected
of BM
Very low Comparison of PCT, CRP and sCD163 levels in patients
with bacterial or viral meningitis, or other infection
Diagnostic value of CRP (AUC = 0.91) and PCT
(AUC = 0.87) superior (p < 0.02 and p < 0.06) to
sCD163 (AUC = 0.72);
sCD163 most specific for systemic bacterial
infection (Sp = 0.91).
PCT/CRP Viallon A [61] Single-centre
observational study
254 adults
(183 VM,
97 BM)
Low Predictive value of serum PCT and CRP for the
diagnosis of BM
AUROC PCT = 0.86; threshold 0.28 μg/mL
(Se = 0.97; Sp = 1, VPP = 0.97, VPN = 1)
AUROC CRP = 0.92; threshold 37 mg/L
(Se = 0.86, Sp = 0.84, VPP = 0.46, VPN = 0.97)
CRP Gerdes L, [62] Meta analysis of 10
studies
Children and
adults
low Predictive value of serum CRP for bacterial meningitis Threshold value for CRP varies across studies
from 19 to 100 mg/l.
Se varies from 92% to 94% and NPV is >97%.
Summary table
Total number of
patients
Highest level of
evidence
Directness* Consistency of
results**
Overall strength of evidence Number of studies
371 Low Yes Yes Low 3 (PCT)
*Directness: studies provide evidence of a direct association between a treatment or a given risk factor and a judgment criterion.
**Consistency: results from studies of similar level of evidence are not contradictory.
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Table 4 Biomarkers and initiation or discontinuation of antibiotic therapy in adult ICU patients with sepsis
Biomarker Study 1st author,
year [ref]
Study design, patient selection
(objective)
Nb of
patients n
Level of
evidence
Primary endpoint and protocol Main results PCT-guided vs. controls
(ARR, absolute risk reduction)
PCT Layios N, [34] Open, randomised controlled trial,
5 ICUs
509 High Total antibiotic use in ICU patients when
using a PCT-based algorithm for initiating
antibiotics (lower PCT threshold for not
initiating therapy: 0.25 ng/mL)
Percent days on antibiotics or overall DDD
did not differ between the two groups.
Withholding or withdrawing antibiotics
similar overall (ARR = 3%) and with low
PCT levels (PCT: 46.3%; controls: 32.7%;
p = NS), or higher levels.
Patients suspected of infection on
admission or during the ICU stay
(initiation of therapy)
PCT: 353
Ctr: 314
PCT Nobre V, [35] Single-centre, open RCT; 79 Moderate Total antibiotic days. ARR antibiotic days: 3.5 (6 vs. 9.5 days;
p = 0.15),
PCT-guided withdrawing antibiotics vs.
“standard care” (duration)ICU patients
with severe sepsis/shock on admission
or during ICU stay (excl.
immunosuppressed patient or requiring
prolonged therapy)
PCT: 39 (31
assessed)*
Recommend stopping antibiotics if PCT
levels ≤ 90% of initial value but not before
Day 3 (if baseline PCT level <1 ng/mL) or
Day 5 (if baseline level ≥ 1 ng/mL).
Less overall ab exposure (504 vs. 655 ab
days; p = 0.28); days alive without
antibiotics at 28 days (15.3 vs. 13.3 days;
p = 0.28). 28-d mortality: 20.5% vs. 20%
Ctr: 40 (37
assessed)*
70% CA
infections
*4 and 2 secondary exclusions for
complicated infections (empyema,
mastoiditis, abscess)
PCT Bouadma L, [33] Multicenter randomised open trial,
7 ICUs
630 High Number of days alive and without
antibiotics; noninferiority in terms of
mortality by using a PCT-based algorithm
for initiating or withdrawing antibiotics in
those suspected of infection on admission
or during the ICU stay (lower PCT
threshold for not initiating or stopping
therapy: 0.25 ng/mL)
ARR: 5% for initiating antibiotics
(PCT: 91% vs. 96% in Ctr group).
Sepsis in ICU patients, on admission or
ICU-acquired (Initiation and duration)
PCT: 311
Ctr: 319 ARR for nb of antibiotic days: 2.7 days
[1.4–4.1]
Ab-free days by 28 d: 11.6 vs. 14.3 days
28-d mortality : 21.2% vs. 20.4%;
ARR = 0.8% [-4.6 to 6.2]
PCT Stolz D, [69] Multicentre open randomised trial,
7 ICUs (duration of therapy for VAP)
101 Moderate Ab-free days alive at 28 days Ab-free days at 28 d: 13 vs. 9.5 days
PCT: 51 Discontinue ab if PCT <0.25 or <0.5 ng/ml
and decrease by >80% from initial level
Ab duration: 10 vs. 15 days
Ctr: 50 28-d mortality: 20% vs. 28%
PCT Hochreiter M, [70] Single-centre open randomised trial 110 Moderate Reduction in ab duration Mean Ab duration: 5.9 vs. 7.9 d
Postoperative sepsis (duration) PCT: 57 Discontinue ab if PCT <1.0 and clinical
improvement, or sustained decrease to
25-35% initial value for 3 days
Mean ICU LOS:
Ctr: 53 28-dMortality: 26.3% vs. 26.4%
PCT Kopterides P, [71] Meta-analysis of RCT in ICU patients
(7 studies)
1131 patients High Various algorithms for discontinuation of
Ab therapy
Duration ab : -2.1 [-2.5 to – 1.8] d
Total Ab exposure: -4.2 [-5 to -3.4] days
Ab free-days: 2.9 [1.9–3.9] days
28-d mortality: OR = 0.93 [0.69-1.26]
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Table 4 Biomarkers and initiation or discontinuation of antibiotic therapy in adult ICU patients with sepsis (Continued)
Summary table: Sepsis in ICU patients
Total number of
patients, n
Highest level of evidence Directness* Consistency** Overall strength of evidence Number of studies, n
1010 High Yes Yes Initiation of therapy: low 7
Discontinuation of therapy: high
*Directness: studies provide evidence of a direct association between a treatment or a given risk factor and a judgment criterion.
**Consistency: results from studies of similar level of evidence are not contradictory.
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were conducted in ICU patients. Although specific stop-
ping rules may vary across trials and population enrolled,
all studies used a PCT-based algorithm to help decide on
stopping antibiotics (Table 5).
In outpatients and emergency room patients (excluding
ICU patients), a serum PCT level below 0.25 ng/mL
obtained 3 days or more after initiation of antibiotics, or a
more than 80% decrease from the peak PCT level, allows
stopping therapy.
Five studies have enrolled ICU patients with community-
or hospital-acquired infection; four used a similar algorithm
and the fifth used a different algorithm. It seems reasonable
to recommend using the algorithm tested on the largest
number of patients, i.e., as in the ProVAP et Prorata studies
[33,69], where stopping therapy was strongly encouraged
when the serum PCT level was <0.5 ng/mL at 3 days or
more after initiating antibiotics, or an >80% decrease from
the maximal serum PCT value was recorded.
Table 5 PCT-based algorithms used for discontinuing antibiotic therapy in randomized, clinical trials
Author [ref], acronym Setting Population Number of patients Algorithm used
Emergency department and ambulatory care
Christ-Crain [18],
ProCAP trial
Emergency room CAP 302 PCT measured d4, d6, d8
- 151 PCT-guided arm Stopping antibiotics encouraged if
PCT < 0.25μg/L; strongly encouraged
if PCT < 0.1 μg/L
- 151 control arm If initial PCT >10μg/L, stop when
decreased by ≥90%
Briel [15] Ambulatory care Lower RTI 458 PCT at d3
- 232 PCT-guided arm Encourage stopping if PCT d3 ≤ 0.25 μg/L
- 226 control arm
Schuetz [25] Emergency room Upper & lower RTI 1359 PCT at d3, d5, d7 if patient still
hospitalised
- 671 PCT-guided arm Stop antibiotics when PCT ≤ 0.25 μg/L
If initial PCT >10 μg/L, stop when
decreased by ≥80%
- 688 control arm
Long W [22] Emergency room CAP 172 PCT at d1, d3, d6, & d8
- 86 PCT-guided arm Stop when PCT ≤ 0.25 μg/L
- 86 control arm
Intensive care unit
Nobre [35] ICU Severe sepsis &
septic shock
79 PCT d1 > 1 μg/l :
- 39 PCT-guided arm • Stop if PCT d5 decreased by > 90% or
PCT < 0.25 μg/L
- 40 control arm PCT d1 < 1μg/l :
• Stop if PCT d3 < 0.1 μg/l
(but not before d5 if bacteremia)
Hochreiter [70] ICU Sepsis 110 Stop if clinical symptoms resolved and
PCT < 1 μg/L (or dropped by 25% - 35%
over 3 days if initial PCT > 1 μg/L)
(Infection + 2 SIRS criteria) - 57 PCT-guided arm
- 53 control arm
Schroeder [73] ICU Severe sepsis after
abdominal surgery
27 Stop if clinical symptoms resolved and
PCT < 1 μg/L (or dropped by 25% - 35%
over 3 days if initial PCT > 1 μg/L)
- 14 PCT-guided arm
- 13 control arm
Stolz [69], ProVAP trial ICU VAP 101 Daily PCT measurements PCT from
d3 on
- 51 PCT-guided arm Stop when PCT < 0.5 μg/L or dropped
by ≥ 80% from initial value but
stopping discouraged if PCT >1 μg/L
- 50 control arm
Bouadma [33],
PRORATA trial
ICU Sepsis, severe sepsis 621 Daily PCT measurements from d3 on
- 307 PCT-guided arm Stop when PCT < 0.5 μg/L or dropped
by ≥ 80% from initial value
- 314 control arm
CAP community-acquired pneumonia, ICU intensive care unit, PCT procalcitonin, RTI respiratory tract infection, SIRS systemic inflammatory response syndrome, VAP
ventilator-associated pneumonia.
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Does the site of infection (known, presumed, unknown)
influence the utility of biomarkers to help withdrawing
antibiotics?
In all studies examining the prognostic and follow-up
value of PCT, the site of infection was known, to the ex-
ception of a few patients (n = 18) in the PRORATA
study (10 and 8 in the PCT arm and control group, re-
spectively). This small number does not allow any con-
clusion for this subgroup. It should be noted that
patients having infective endocarditis, bone and joint
infection, acute mediastinitis, intracerebral or intra-
abdominal abscess were excluded from the above stud-
ies. Therefore, PCT-based algorithms cannot be used in
these patients for discontinuing antibiotics.
Therefore, PCT-guided interruption of therapy can be
used as indicated above in patients having a clinically
documented site of infection to the exception of those
sites listed above, which were excluded from clinical tri-
als. When the site of infection is unknown, insufficient
data are available to make a recommendation.
Does microbiological documentation influences the
clinical utility of biomarkers to help withdrawing
antibiotics?
Microbiologically documented infection
In the PRORATA study, most patients enrolled (70%)
had microbiologically documented infection (222 and
213 in the PCT and control group, respectively) [33]. In
the subgroup of 108 patients having positive blood cul-
tures (55 and 53 in the PCT and control group, respec-
tively), those randomised to the PCT-guided algorithm
received 3 days less antibiotics than those enrolled in the
control group (IC95%, -6 to 0.1 day, p = 0.06), without
difference in mortality rate.
In the ProHosp trial, 72 patients had positive blood
cultures [25]; patients enrolled in the PCT-guided ther-
apy group received 5 days less antibiotics (10.3 vs. 15.1
days). Among 237 patients with bacteremic LRTI in-
cluded in a recent meta-analysis [32], those treated with
the aid of a PCT-based algorithm had 3.5 less antibiotic
days (95% CI 1.55-5.54, p < 0.001), without significant
difference in mortality rate (OR 1.09; 95% CI 0.51-2.31).
Lack of microbiological documentation
Most studies conducted outside of the ICU have enrolled
patients in whom microbiological documentation was
lacking. Although this specific subgroup has not been ex-
amined separately in individual studies or meta-analyses,
it seems reasonable to recommend using a PCT algorithm
in the non-ICU population to help decide stopping anti-
biotic therapy.
Most ICU patients enrolled in the above mentioned stud-
ies had documented infection. However, in the PRORATA
study [33], 186 episodes were nondocumented and those
treated in the PCT-guided therapy arm had a nonsignifi-
cant reduction in antibiotic days (2.4 less days), with no
difference in mortality rate. Therefore, the documentation
of infection does not appear to influence the impact of
PCT-guided withdrawal of therapy, whether in ICU or
non-ICU populations.
Does an immunocompromised status of patients
influence the use of biomarkers for stopping antibiotic
therapy?
Among the nine trials testing the impact of PCT-guided
discontinuation of therapy, only the PRORATA trial [33]
enrolled immunocompromised patients in the ICU. This
trial enrolled patients having HIV infection or AIDS,
organ transplant recipients, patients having haemato-
logical malignancy or receiving chemotherapy or radi-
ation therapy, immunosuppressive agents or long-term
steroids, to the notable exception of bone marrow trans-
plant recipients or those having severe neutropenia
(<500 leucocytes/mm3). About a hundred such immuno-
compromised patients were included (47 and 51 in the
PCT-guided therapy group and control group, respect-
ively). In this subgroup, PCT-guided discontinuation of
therapy was associated with a significantly reduced dur-
ation of therapy (3.6 days; 95% CI, 0.2-7 days), without
apparent effect on morbidity or mortality (control vs.
PCT, -7.1%; 95% CI −18.7 to 4.5%).
Therefore, PCT-guided algorithms to reduce the dur-
ation of antibiotic therapy can be used safely in immuno-
compromised patients, to the exception of neutropenic
patients (<500 neutrophils/mm3) or bone marrow trans-
plant recipients, which were excluded from trials and in
whom PCT-guided therapy cannot be recommended.
Does the impact of PCT-guided therapy vary according to
the severity of acute illness?
Systematic reviews and meta-analyses
Six studies were reviewed in the meta-analysis by Tang et al.
[74], totalling 1,548 patients. Four of these trials enrolled
patients with suspected LRTI, two studies enrolled pa-
tients with sepsis, and one focused on severe infections in
surgical ICU patients. Algorithms used varied across stud-
ies, using 2, 3, or 4 PCT levels for decision-making. There
was a nonsignificant trend to a reduced duration of anti-
biotic therapy among LRTI studies (p = 0.067), which
showed significant heterogeneity between trials. Con-
versely, in the other three studies of sepsis and surgical pa-
tients that enrolled more severe patients, no substantial
heterogeneity was observed, and PCT-based algorithm for
discontinuation of antibiotics were associated with a sig-
nificant reduction in antibiotic duration, without apparent
deleterious effect. This meta-analysis did not, however,
stratify trials according to the severity of illness. In the
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subgroup of four studies having the strongest design (in-
cluding 3 of the 4 studies on LRTI), there was a significant
reduction in the duration of antibiotic therapy, but a sig-
nificant heterogeneity persisted.
Significant heterogeneity also was evidenced in a recent
meta-analysis including eight studies of LRTI [75]. There
was one trial in patients with acute exacerbation of COPD,
one on patients with CAP, two on patients with upper and
lower RTI [16], and three on LRTI. A significant reduction
of antibiotic duration was noted in all but one study [16],
where a PCT-based algorithm was not used. Similarly to
the previous analysis, this meta-analysis did not stratify
patients according to their severity.
In the more recent systematic review by Schuetz et al.
focusing on LRTI [32], 14 trials totalling 4,221 patients
were analysed. A reduced rate of treatment initiation
was confirmed in studies performed in primary care and
patients having upper or lower RTI or acute bronchitis.
Trials performed in the emergency department or the
ICU and enrolling patients with LRTI, whether CAP or
VAP, also found a reduction in the duration of antibiotic
therapy. A sensitivity analysis showed no significant dif-
ference in the reduction of antibiotic duration according
to the type of LRTI and site of care. It was however
noted that the observance of clinical algorithms was
lower in the ICU setting than at other sites.
Individual studies
Christ-Crain et al. [18] reported that PCT levels in-
creased with the severity of illness, as assessed by the
pneumonia severity index (PSI). However, the duration
of antibiotic prescription decreased similarly with PCT-
guided therapy in the low-risk (PSI I-III) or high-risk
(PSI IV-V) group. In another study in patients with LRTI
from the same group [17], only admission PCT levels
were recorded but not duration of therapy. In the
PROHOSP study [25], the reduction of antibiotic dur-
ation with PCT-guided therapy was more marked among
patients having acute bronchitis (−65%) than among pa-
tients with acute exacerbation of COPD (−50%), and
lowest (−32%), but still strongly significant, among those
with CAP.
In the trial conducted by Stolz et al. in patients with
acute exacerbation of COPD [20], the impact of PCT-
guided therapy was not analysed according to the sever-
ity of the episode or of the underlying COPD, which in-
cluded all severity stages.
Briel et al. enrolled patients with RTI from various
causes, including upper respiratory tract infection or
acute bronchitis, CAP, or acute exacerbation of COPD
[15]. The reduction in antibiotic duration was more
marked in the former group than in those with CAP or
acute exacerbation of COPD.
The proREAL trial also enrolled patients (n = 1,759)
with acute bronchitis, exacerbation of COPD, and CAP
[27]. The observance of the algorithm was 81%, 70%,
and 64% respectively, confirming other observations
[32,33] that the observance decreases with increasing
severity of illness. Of note, the algorithm used in that
study included both the clinical context and PCT levels
(Table 3).
Long et al. also found a reduction in antibiotic dur-
ation of patients with CAP [22]. However, this study en-
rolled only patients with nonsevere pneumonia and
cannot inform this assessment according to severity of
illness. In trials dealing with the more severe infections
(VAP, sepsis) [33,35,65,66], analyses have not been strati-
fied according to the level of severity.
Summary and conclusions
In view of currently available data, PCT is the only bio-
marker that has been extensively studied so far to help
decision-making in discontinuing antibiotic therapy in
adults. In clinical practice, an algorithm should be used,
based on PCT levels on day 1 (reference value), then at
day 2–3, and every 48 h until antibiotic therapy is
stopped.
In nonimmunocompromised patients treated for RTI
as outpatients or hospitalised in regular wards, the fol-
lowing stopping rule can be used: discontinuation of
antibiotic therapy if the PCT level at day 3 is lower than
0.25 ng/mL or has decreased by >80-90% relative to the
maximal value initially recorded, whether or not micro-
biological documentation has been obtained.
For patients hospitalised in ICU, including immuno-
compromised patients (but not neutropenic patients or
bone marrow transplant recipients), the following deci-
sion rule can be suggested for nonbacteremic patients
with a known site of infection (whether or not microbio-
logical documentation is obtained): stopping antibiotics
if the PCT level at day 3 is <0.5 ng/ml or has decreased
by >80% relative to the highest level recorded during this
episode. In bacteremic patients, a minimal duration of
therapy of 5 days is recommended.
Overall, the severity of the infectious episode does not
appear to alter substantially the impact of PCT measure-
ments on the reduction of antibiotic duration; however,
the magnitude of the reduction is more marked in infec-
tions of lesser severity, which likely reflects at least two
factors: 1) the less common indications for antibiotic
therapy in such conditions, which is in contrast to the
high tendency among physicians to initiate therapy when
in doubt on the aetiology; 2) the better observance of
decision algorithms by physicians, likely related to their
greater confidence in the lack of serious risk associated
with withholding or withdrawing antibiotics in these
low-severity patients.
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